Genmab — Januar 2021
-
...og hæng nu godt fast. Følgende sakset fra Børsen - "Jeg forventer en betydeligt højere vurdering af Genmab
Frank Hørning Andersen, tidligere aktieanalytiker i Jyske Bank" -
Vorherre elsker en omvendt synder. Nu mangler vi bare at lære FF at sige epcoritamab
-
Peter Verdult estimerer JNJ tilbageholder 1% af royaltybetalingen til Genmab relateret til voldgiftsagen (iflg. Børsen).
-
244 stille deltagere i chatten lige nu.
-
Resultatet er nu ude
-
Ingen reaktion...endnu..
-
Ingen detaljer endnu
-
JNJ 1% op
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind